

# Index

## A

- Abnormal GERD, LTX recipients
  - description, 208
  - gastric motility, 211
  - postoperative oropharyngeal dysphagia, 212
  - prevalence, 208–210
- Acid
  - aromatic amino, 26
  - BA, 27
  - fatty, 27
  - gastric, 24–25
  - hydrochloric, 25
  - reflux, 32
  - stomach, 27
  - taurocholic, 27
- Acid-suppressing agents
  - adverse effects, H2-RA therapy, 236
  - adverse events, 240
  - CDI, 242
  - description, 233
  - drug-drug interactions, 243
  - H2-RAs, 235–236
  - nocturnal, 109
  - parietal cell, 234–235
  - pH, 234
  - PPI (*see* Proton pump inhibitors (PPIs))
- Aerodigestive tract reflexes, 10, 11, 26, 36
- Airway protection
  - and closure, 2
  - and deglutition, 10, 19
  - function, 9
  - motor actions, 17–18
  - and pharynx, 12
  - reflex, 7, 8, 14–16
- Alginic acid, 233
- Antacids, 232
- Anti-reflex surgery
  - defined, 168
  - evaluation, 131
  - fundoplication, 35
  - recreation, anatomical barrier, 219
- Arousals
  - causes, 145
  - omeprazole, 141
  - OSA events, 143
  - response, 138, 146
  - and sleep architecture, 138, 146
- Aspiration. *See also* Children, GERD
  - and aspiration
  - acidic secretions, 180
  - bronchiolitis, 188
  - chronic, 180
  - elderly
    - age-related changes, pulmonary immunity, 88, 89
    - modifications, oropharyngeal flora, 88
    - morbidity and mortality, 87
    - pneumonia, 87, 88
    - prevention and treatment, 88–90
  - food particles, 188
  - gastric fluid, 180
  - intradeglutitive, 18
  - laryngopharyngeal sensory thresholds, 17
  - and pneumonia, 18
  - pneumonitis, 178
  - postoperative, 192
  - puree, 12, 13
  - refluxate, 190
  - repetitive, 182
  - residue, 12
  - silent, 5–6

- Aspiration of gastric content, CF and NCFB, 161–162
- Asthma
- aspiration, gastric contents, 126–127
  - description, 121
  - diagnosis (*see* Gastroesophageal reflux disease (GERD))
  - embryonic origins, 124–125
  - increased bronchial reactivity, 126
  - medical therapy, 129–130
  - nervous system, 125–126
  - prevalence, 122–123
  - and reflux, 59–60
- Autoimmune diseases, 2, 98
- B**
- BA. *See* Bile acids (BA)
- BALF. *See* Bronchoalveolar lavage fluid (BALF)
- Barrett's esophagus, 15, 24, 32, 77, 84
- Bethanechol, 244
- Bile acids (BA)
- administration, agents, 220
  - defined, 26–27, 207
  - detection, BALF, 211, 213
  - GER and aspiration, 213
- BO. *See* Bronchiolitis obliterans syndrome (BOS)
- BPD. *See* Bronchopulmonary dysplasia (BPD)
- Bronchiectasis, 206
- Bronchiolitis obliterans syndrome (BOS)
- biopsy specimens, 212
  - chronic allograft rejection, 201
  - ColV sensitization, 215
  - defined, 62
  - HRCT imaging, 214
  - OB, 212
  - stages, 214
- Bronchoalveolar lavage fluid (BALF), 101, 256
- Bronchopulmonary dysplasia (BPD)
- aspirated material, 58
  - babies, 66
  - pepsin levels, 63
  - symptoms, 62
- C**
- CA. *See* Carbonic anhydrase (CA)
- Carbonic anhydrase (CA), 28, 31
- CDI. *See* *Clostridium difficile* infection (CDI)
- Central pattern generator (CPG), 8, 9, 11
- Chest physiotherapy (CPT), 61, 166
- Children, GERD and aspiration
- apnea and reflux, 63
  - BO and reflux, 59–60
  - BO and reflux, 59
  - bronchiectasis and reflux, 61
  - chronic lung disease, infancy and reflux, 62–63
  - diagnosis
    - antisecretory agents, 64
    - esophageal pH monitoring, 65
    - MII, 65
    - nuclear scintiscan/milk scan test, 65
    - salivagram and LLMI, 66
    - symptoms, reflux, 64
  - medical management, 68–69
  - medical treatment, 67–68
  - recurrent croup and reflux, 63–64
  - recurrent pneumonia and reflux, 60–61
  - and reflux, lung disease, 57–59
  - surgical treatment, 68–70
  - syndromes, reflux, 59
- “Chronic cough hypersensitivity syndrome”, 102
- Chronic obstructive pulmonary diseases (COPD)
- description, 121
  - diagnosis (*see* Gastroesophageal reflux disease (GERD))
  - medical therapy, 130–131
  - pathophysiology, 127
  - prevalence, 123–124
- Clostridium difficile* infection (CDI)
- broad-spectrum antibiotics, 242
  - and pneumonia, 240
  - PPIs (*see* Proton pump inhibitors (PPIs))
- Collagen V (ColV), 215
- ColV. *See* Collagen V (ColV)
- Computed tomogram (CT), 104, 190, 216
- Connective tissue disorders (CTD)
- CTD-ILD, 185–187, 220
  - dilated esophagus, 185, 187
  - HRCT, 185
  - MCTD, 185
  - non-scleroderma, 206
  - scleroderma, 188, 202
- Continuous positive airway pressure (CPAP)
- defined, 144
  - nasal, 144, 145, 148
  - OSA treatment, 145
- COPD. *See* Chronic obstructive pulmonary diseases (COPD)
- Cough
- asthma-related symptoms, 122
  - capsaicin, 126

- chronic, 123
- humans, 126
- CPAP. *See* Continuous positive airway pressure (CPAP)
- CPG. *See* Central pattern generator (CPG)
- CPT. *See* Chest physiotherapy (CPT)
- CT. *See* Computed tomogram (CT)
- CTD. *See* Connective tissue disorders (CTD)
- Cystic fibrosis (CF)
  - children, bronchiectasis, 61
  - and NCFB, GERD
    - anamnesis, 159
    - aspiration, gastric content, 161–162
    - CPT, 166
    - defined, 155–156
    - DGER, 161
    - esophageal factors, 165
    - gastric factors, 163
    - “gold standard” method, 157
    - NERD and ERD, 161
    - prevalence study, 156–158
    - reflux and aspiration effects, lung disease, 166–169
    - reflux characteristics, children and adults, 160, 161
    - sphincteric factors, 163–165

**D**

- Defense mechanisms, esophageal mucosa
  - epithelial
    - CA, 31
    - EGF, 30
    - heat shock proteins, 32
    - Na<sup>+</sup>-dependent Cl<sup>-</sup>/HCO<sub>3</sub><sup>-</sup>-exchanger, 32
    - Na<sup>+</sup>/H<sup>+</sup> exchanger, 31
    - structural, 29–30
    - TGF, 30–31
  - post-epithelial, 32
  - pre-epithelial
    - LES, 28
    - peristalsis, 28
    - saliva, 28–29
- Deglutition
  - CPG, 8
  - defined, 1
  - dysfunctional, 16–19
  - esophageal phase, 7–8
  - oral preparatory phase, 2–4
  - oral propulsive phase, 4–5
  - pharyngeal phase, 5–7
  - swallows, neural pathway, 8–9
- Dermatomyositis, 79
- DES. *See* Diffuse esophageal spasm (DES)

- DGER. *See* Duodenogastroesophageal reflux (DGER)
- Diabetes mellitus, 79, 88
- Diagnosing GERD
  - and IPF, 257
  - and therapy selection, 252–253
- Diffuse esophageal spasm (DES), 78, 81
- Dorsal vagal complex, 15
- Duodenogastroesophageal reflux (DGER), 161, 163
- Dysphagia
  - causes, bolus transfer, 16
  - esophageal
    - GERD, 77
    - medications, 78
    - strictures, 77
  - oropharyngeal
    - Parkinson’s disease, 76
    - stroke, 75–76
    - structural lesions, 76–77
    - Zenker’s diverticulum, 76
  - and pneumonia, 18

**E**

- ECLs. *See* Enterochromaffin-like cells (ECLs)
- EEG. *See* Electroencephalogram (EEG)
- EER. *See* Extra-esophageal reflux (EER)
- Elderly patients
  - aspiration, 87–90
  - GERD (*see* Gastroesophageal reflux disease (GERD))
  - swallowing disorders (*see* Swallowing disorders, elderly)
- Electroencephalogram (EEG), 138
- Endoluminal therapy
  - description, 263–264
  - EsophyX system, 265
  - GE junction and LES, 264
  - LES pressure, 264–265
  - PPI therapy and symptoms, 264
  - radiofrequency technique, 265
  - TIF, 264
- Endoscopic approaches. *See* Gastroesophageal reflux disease (GERD)
- Endoscopy, 45, 46
- Enterochromaffin-like cells (ECLs), 234–235
- Epidermal growth factor (EGF)
  - defined, 30
  - production, 29
  - and TGF- $\alpha$ , 30–31
- ERD. *See* Erosive reflux disease (ERD)
- Erosive reflux disease (ERD), 159, 161
- Esophago-bronchial reflex, 101–102

## Esophagus

- adenocarcinoma, 77
- CA, 31
- distal, 33
- gastric contents, 23
- intermittent exposure, 33
- pepsin, 26
- peristalsis, 28
- reflux, gastric acid, 25
- saliva, 29

Exhaled breath condensate (EBC), 216–217

Extra-esophageal reflux (EER), 24, 36

**F**

FEESSST. *See* Functional endoscopic evaluation of swallowing with sensory testing (FEESSST)

Functional endoscopic evaluation of swallowing with sensory testing (FEESSST), 14, 17, 65, 66, 101

**G**

GABA. *See* Gamma-aminobutyric acid (GABA)

Gamma-aminobutyric acid (GABA), 245–246

Gastroesophageal pressure gradient (GEPG), 165, 169

Gastroesophageal reflux disease (GERD).

- See also* Children, GERD and aspiration; Cystic fibrosis (CF); Sleep-related GERDacid suppression, 109–110

algorithm, diagnosis, 112–113

ambulatory pH monitoring, 48–50

and aspiration diagnosis

- biomarkers, 216
- description, 215
- distal and proximal esophagus, 215
- EBC, 216–217
- pyloroplasty, 217
- radiologic techniques, 216
- suppression pharmacologic therapies, 216

“aspirators”, 251

asthma (*see* Asthma)

and autoimmunity, 215

bile, 26–27

causes, 104, 105

chronic cough, 98–99

complexities, 14, 262–263

vs. control subjects, normal pH-metry, 17

COPD (*see* Chronic obstructive pulmonary diseases (COPD))

cough reflex hypersensitivity, 102

CTD-ILD, 188

defense mechanisms (*see* Defense mechanisms, esophageal mucosa)

defined, 23, 43, 229, 251

detection, 105–106

elderly

- altered esophageal pain perception, 84

- barium swallow, 84

- heartburn, 83

- prevention and treatment, 85–87

- symptoms, 82–83

endoluminal therapy (*see* Endoluminal therapy)

endoscopy, 45, 46

end-stage lung disease, 251

esophago-bronchial reflex, 101–102

and extraesophageal reflux, 231

gastric acid, 24–25

ILD (*see* Interstitial lung disease (ILD))

indications, surgical management, 253–254

and LPR (*see* Laryngopharyngeal reflux (LPR))

lung allograft dysfunction (*see* Lung allograft dysfunction)

lung disease, 202–207

manometry, 46–48

measurements, laryngopharyngeal sensitivity, 14

microaspiration, 101

non-acidic stimulation, cough, 102–103

nonacid reflux, laryngeal inflammation disease, 34–36

non-invasive biomarkers, 113

operative technique (*see* Operative technique, GERD)

pathophysiology, 33

pepsin, 25–26

pharmacologic treatment (*see* Pharmacologic treatment, GERD)

pneumonia, 188

pulmonary symptoms, 252

reflux and cough, 107–108

reflux and symptoms, 44

severity and frequency, symptoms, 179

“step-up” strategy, 231

surgical

- management, 254

treatment (*see* Surgical management)

symptoms, 122, 231

testing modalities, reflux, 51–53

therapy selection and diagnosing, 252–253  
 treatment and prevention, 217–219  
 trypsin, 27–28  
 UGI esophagram, 45–46  
 VCD (*see* Vocal cord dysfunction (VCD))  
 GEPG. *See* Gastroesophageal pressure  
 gradient (GEPG)  
 GER. *See* Gastroesophageal reflux disease  
 (GERD)  
 GERD. *See* Gastroesophageal reflux disease  
 (GERD)

## H

HH. *See* Hiatal hernias (HH)  
 Hiatal hernias (HH)  
 CT scanning, 190, 216  
 defined, 164–165  
 diffuse pulmonary fibrosis, 182  
 EGD, 45, 46  
 high-resolution manometry tracing, 48  
 and mediastinal esophageal dissection, 261  
 multi-detector computed tomography, 185  
 prevalence, 83  
 sliding, 45  
 symptoms, dysphagia, 192  
 UGI esophagram, 46, 47  
 High-resolution computed tomography  
 (HRCT)  
 changes, UIP, 182  
 fibrosis  
 degree, 193  
 radiologic, 185  
 scores, 191, 256  
 imaging, 188  
 Histamine type 2 receptor antagonists  
 (H2-RAs)  
 acid-suppressant medications, 235  
 adverse effects, 236  
 clinical studies, 236  
 description, 235  
 “on-demand” therapy, 236  
 oral absorption, 235  
 H2-RAs. *See* Histamine type 2 receptor  
 antagonists (H2-RAs)  
 HRCT. *See* High-resolution computed  
 tomography (HRCT)

## I

Idiopathic pulmonary fibrosis (IPF)  
 abnormal GER, 182  
 abnormal proximal/distal esophageal  
 acid, 256

description, 180–181  
 diagnosis, 255  
 distal esophagus, 184  
 GER and pulmonary fibrosis, 182–184  
 HH, 185  
 HRCT, 182  
 mutations, 181  
 NSIP, 182  
 parenchymal lung diseases, 255  
 PPIs, 184–185  
 proximal and distal esophageal acid,  
 182–183  
 UIP, 181–182  
 ILD. *See* Interstitial lung disease (ILD)  
 Impedance-pH monitoring  
 detection, acid and non-acid reflux,  
 105, 106  
 detection, pharyngeal reflux, 113  
 esophageal, 107, 108  
 Insomnia  
 predictors, sleep-related heartburn,  
 139, 140  
 sleep-related GER, 141, 146  
 Interstitial lung disease (ILD)  
 animal and in vitro studies, 179–180  
 aspiration (*see* Aspiration)  
 CTD (*see* Connective tissue disorders  
 (CTD))  
 DeMeester score, 188  
 description, 177  
 diagnosis, 189–190, 255  
 GER and microaspiration, 178–179  
 IPF (*see* Idiopathic pulmonary fibrosis  
 (IPF))  
 nodular granulomatous inflammatory  
 process, 188  
 progressive type, 255  
 treatment, 191–192  
 UIP, 178  
 IPF. *See* Idiopathic pulmonary fibrosis (IPF)

## L

Laparoscopic anti-reflux surgery (LARS)  
 BOS and BAL, 256  
 esophageal dysfunction and aspiration, 255  
 GERD symptoms, 256  
 HRCT and UIP, 255  
 ILD and IPF, 255  
 pharmacologic treatment, IPF, 256  
 prevention, 257–258  
 LARS. *See* Laparoscopic anti-reflux surgery  
 (LARS)  
 Laryngeal inflammation disease, 34–36

- Laryngeal protection  
 aerodigestive tract protective reflexes, 10, 11  
 bolus transfer, 16  
 changes, sleep, 15  
 esophagoglottal reflex, 14  
 esophago-UES contractile reflex, 13  
 functions, 9  
 laryngeal reflexes, 14  
 LES (*see* Lower esophageal sphincter (LES))  
 molecular vehicles and receptors, 19  
 motor disorders, 17–18  
 pharyngoglottal reflex, 12–13  
 pharyngo-UES contractile reflex, 12  
 PRS/secondary pharyngeal swallow, 12  
 sensory disorders, 16–17  
 timing disorders, 18–19  
 UES (*see* Upper esophageal sphincter (UES))
- Laryngeal reflexes, 14
- Laryngopharyngeal reflux (LPR)  
 defined, 24  
 esophagitis and laryngitis, 34  
 hoarseness, 33  
 and microaspiration, 103  
 oropharynx, 231  
 pathophysiology, 33  
 prevention, 265
- Larynx  
 aditus, 5  
 aspiration pneumonia, 87, 178  
 functions, 9  
 removal, 5
- LES. *See* Lower esophageal sphincter (LES)
- Lipid-laden macrophage index (LLMI), 52–53, 66, 167
- LLMI. *See* Lipid-laden macrophage index (LLMI)
- Lower esophageal sphincter (LES)  
 body dysmotility, 206  
 COPD, 127  
 hypotonia, 206  
 intrinsic esophageal muscle thickening, 14  
 pressure, 127–128, 264–265  
 swallow-induced relaxation, 15  
 and UES function, 212
- LPR. *See* Laryngopharyngeal reflux (LPR)
- Lung allograft dysfunction  
 BOS, 212  
 cough reflex, 213  
 description, 212  
 esophageal motility, 212  
 esophageal pH probe, 213  
 histopathology, OB, 212, 214  
 HRCT imaging of BOS, 212, 214  
 microaspiration, 213  
 PPI therapy, 214–215  
*Pseudomonas aeruginosa* and *Aspergillus*, 212
- Lung disease  
 CF and NCFB  
 acid suppression, 168  
 antireflux surgery, 168  
 diagnostic tools, 169  
 end-stage bronchiectasis, 169  
 LLMI, 167  
 Pa, 167  
 chronic, infancy and reflux/aspiration, 62–63  
 CTD, 202  
 esophageal abnormalities, HRCT, 202, 206  
 esophageal dysmotility and gastroparesis, 206  
 LES and ESLD, 206  
 LPR, 206  
 LTx, 202–205  
 MCTD, 206–207  
 microaspiration, 207  
 reflux and aspiration mechanisms, children, 57–59  
 symptoms, 202
- Lung transplantation (LTx)  
 abnormal GERD (*see* Abnormal GERD, LTx recipients)  
 bronchiolar injury, 201–202  
 description, 201  
 diagnosis, aspiration, 215–217  
 gastric juice, 207–208  
 GERD (*see* Gastroesophageal reflux disease (GERD))  
 lung allograft dysfunction (*see* Lung allograft dysfunction)  
 treatment and prevention, 217–219
- M**
- Manometry  
 high-resolution tracing, 48  
 LES, 46–47  
 peristaltic waveform, 47
- MCTD. *See* Mixed connective tissue disease (MCTD)
- Mechanisms for reflux and aspiration, lung disease  
 antegrade, 58  
 defined, 57–58  
 gastric contents, 58  
 TEF, 59

- Metoclopramide, 244
- Microaspiration  
 abnormal GER, 178  
 allograft dysfunction, 213  
 biomarkers, 193  
 chronic, 131  
 gastric juice, 191  
 ILD, 207  
 IPF vs. GER, 191  
 lung disease exacerbation, 193  
 lung resistance, 126  
 pathogenesis, 193  
 PEF, 126  
 Pepsin and BA, 213  
 proximal gastrointestinal tract, 201  
 pulmonary parenchymal changes, 216  
 “silent”, 178  
 transverse HRCT, prone positioning, 179
- MII. *See* Multichannel intraluminal impedance (MII)
- Mixed connective tissue disease (MCTD)  
 and esophageal motility, 185  
 lung parenchymal abnormalities, 188  
 non-scleroderma CTD, 185
- Motor disorders, 17–18
- Multichannel intraluminal impedance (MII),  
 34, 35, 65
- N**
- Nasal CPAP, 144, 145, 148
- NERD. *See* Nonerosive reflux disease (NERD)
- Neurodegenerative diseases, 18, 88
- Neuromuscular/motility disorders  
 achalasia, 78  
 amyloidosis, 79  
 causes, dysphagia, 79  
 dermatomyositis, 79  
 DES, 78  
 prevention and treatment, 80–81  
 rheumatoid arthritis, 78–79  
 therapeutic modes, dysphagia, 81–82  
 thyrotoxicosis, 79
- Nissen fundoplication  
 antireflux operation, 258  
 endoluminal plication, 264  
 GERD and respiratory symptoms, 253  
 laparoscopic approach, 254
- Nonacid reflux, laryngeal inflammation  
 disease  
 anti-reflux fundoplication surgery, 35  
 multichannel intraluminal impedance,  
 pHmonitoring, 34  
 pepsin, 35–36
- Non-CF bronchiectasis (NCFB). *See* Cystic  
 fibrosis (CF)
- Nonerosive reflux disease (NERD), 159, 161
- Nonspecific interstitial pneumonia (NSIP), 182
- NSIP. *See* Nonspecific interstitial pneumonia  
 (NSIP)
- O**
- OB. *See* Obliterative bronchiolitis (OB)
- Obliterative bronchiolitis (OB)  
 CLAD, 201  
 histopathology, 212, 213
- Obstructive sleep apnea (OSA). *See* OSA  
 and sleep-related GERD
- Operative technique, GERD  
 completed 2-cm floppy Nissen, 261, 262  
 description, 259–260  
 dietary guidance, 262  
 gastrohepatic ligament, 260  
 GE junction, 261  
 Nissen fundoplication, 260  
 penrose drain, 261  
 phrenogastric ligament, 260  
 pneumoperitoneum, 260  
 toupet fundoplication, 262
- OSA and sleep-related GERD  
 abnormal esophageal acid, 143  
 CPAP, 144  
 defined, 142  
 surgical treatment, 144–145  
 UES, 144
- OTC. *See* Over-the-counter (OTC)
- Over-the-counter (OTC)  
 acid-neutralizing medications, 229–230  
 meta-analysis, randomized controlled  
 trials, 233
- P**
- Pa. *See* *Pseudomonas aeruginosa* (Pa)
- Paradoxical vocal fold motion (PVFM),  
 60, 97. *See also* Vocal cord  
 dysfunction (VCD)
- Parkinson’s disease, 76
- Peak expiratory flow (PEF), 126
- PEF. *See* Peak expiratory flow (PEF)
- Penetration  
 and aspiration, 5–6, 13  
 laryngeal, 18  
 nonsmokers, pharyngeal anesthesia, 17  
 pharyngeal reflexive swallows, 12  
 testing, aryngopharyngeal sensory  
 thresholds, 17

- Pepsin  
 and BA, 35  
 defined, 25–26  
 nonacid reflux, 35  
 saliva measurement, 113  
 sputum analysis, 51
- PES. *See* Pharyngoesophageal segment (PES)
- PF. *See* Pulmonary fibrosis (PF)
- pH  
 ambulatory monitoring  
   catheter and Bravoprobe, 49  
   parameters, measurements, 49  
   tracing, 50  
 impedance testing, 50–51
- Pharmacologic treatment, GERD  
 acid-suppressing agents (*see* Acid-suppressing agents)  
 cholinergic prokinetic agents, 244  
 combination therapy, 246  
 description, 229  
 dopaminergic antagonist prokinetic agents, 244  
 GABA receptor prokinetic agents, 245–246  
 GERD (*see* Gastroesophageal reflux disease (GERD))  
 maintenance therapy, 246–247  
 OTC, 229–230  
 reflux-moderating agents (*see* Reflux-moderating agents)  
 serotonin receptor prokinetic agents, 244–245
- Pharyngeal pHmetry technique, 106
- Pharyngeal reflexive swallow (PRS), 12, 17
- Pharyngoesophageal segment (PES)  
 bolus, 5  
 closure, 8  
 opening, 5, 8–9, 11–12  
 outlet obstruction, 6  
 residue, 12
- Postnasal drip, 98
- Postprandial acid pocket, 162, 165
- Power spectral analysis, sleep EEG, 138
- PPIs. *See* Proton pump inhibitors (PPIs)
- Proteolysis, 25
- Proton pump inhibitors (PPIs)  
 adverse events, 240  
 benzimidazole derivatives, 237  
 CDI (*see* *Clostridium difficile* infection (CDI))  
 dose, 113, 147  
 double-dose treatment, 231  
 drug-drug interactions, 243  
 esophageal acid exposure, 256  
 formulations, 147, 239–240  
 and GER symptoms, 264  
 healing-time curves, 237  
 H<sup>+</sup>/K<sup>+</sup> ATPase, 238  
 H2-RAs, 230  
 and LARS, 254  
 metabolism, 239  
 oral, 102, 104, 109  
 and osteoporosis-related fractures, 241–242  
 pharmacodynamic profiles, 238  
 pharmacokinetic properties, 238, 239  
 PPI + nocturnal H2-RA, 236  
 prodrug accumulation, 237  
 work productivity, 141
- PRS. *See* Pharyngeal reflexive swallow (PRS)
- Pseudomonas aeruginosa* (Pa), 167, 212, 215, 256
- Pulmonary fibrosis (PF), 202, 206–207
- PVFM. *See* Paradoxical vocal fold motion (PVFM)
- R**
- Reflexive pharyngeal swallow (RPS), 7, 17
- Reflux  
 LLMI, 52–53  
 sputum pepsin analysis, 51  
 and symptoms, 44
- Reflux induced cough, 102, 109, 110
- Reflux-moderating agents  
 adverse effects, 232–233  
 alginic acid, 233  
 antacids, 232
- Rheumatoid arthritis, 78–79
- RPS. *See* Reflexive pharyngeal swallow (RPS)
- S**
- Scleroderma  
 CTD-ILD, 188  
 and IPF, 192  
 surgical lung biopsies, 188  
 visceral organs, 185
- Selecting the best therapy, 252–253
- Sensory disorders  
 esophagus, 17  
 nonsmokers, 17  
 Zenker diverticulum, 16, 17
- Sleep quality, 141, 142, 145
- Sleep-related GERD  
 distribution, acid-reflux events, 137, 138  
 EEG, 138  
 esophageal pH monitoring, 138  
 esophageal pH testing, 145



- laryngospasm, 142
  - omeprazole, 141
  - and OSA (*see* OSA and sleep-related GERD)
  - prevalence, 139–140
  - prevention, 140, 141, 145–146
  - surgical fundoplication, 147–148
  - treatment, 147
  - Stroke, 75–76
  - Surgical approaches. *See* Gastroesophageal reflux disease (GERD)
  - Surgical management, GERD
    - contraindications, 254
    - symptoms, 253
    - treatment
      - description, 254
      - LARS (*see* Laparoscopic antireflux surgery (LARS))
      - partial vs. fundoplication, 258–259
      - PPI therapy, 254
  - Swallowing disorders, elderly
    - changes, 74
    - esophageal dysphagia, 77–78
    - malnutrition, 75
    - medications, dysphagia and GERD risk, 75
    - neuromuscular/motility disorders, 78–82
    - oropharyngeal dysphagia, 75–77
- T**
- TEF. *See* Tracheoesophageal fistulas (TEF)
  - TGF- $\alpha$ . *See* Transforming growth factor alpha (TGF- $\alpha$ )
  - Thyrotoxicosis, 79
  - TIF. *See* Transoral incisionless fundoplication (TIF)
  - Timing disorders, 18–19
  - Tracheoesophageal fistulas (TEF), 59, 61, 69
  - Transforming growth factor alpha (TGF- $\alpha$ ), 30–31
  - Transient LES relaxations
    - defined, 136, 142, 145
    - frequency, 147
    - OSA events, 143
    - tors, 137
  - Transoral incisionless fundoplication (TIF), 264–265
  - Treatment strategies, reflux disease
    - double-dose PPI treatment, 231
    - H2-RA-based therapy, 231
    - LPR, 231–232
  - PPI acid, 231
  - pyramidal protocol, 231
  - “step-up” therapy, 230–231
  - Trypsin, 27–28
- U**
- UES. *See* Upper esophageal sphincter (UES)
  - UGI series. *See* Upper gastrointestinal (UGI) series
  - UIP. *See* Usual interstitial pneumonia (UIP)
  - Upper esophageal sphincter (UES)
    - anatomic components, 10
    - dermatomyositis, 79
    - esophago-UES contractile reflex, 13
    - factors, pressures, 11
    - function, 33
    - hypotonia, 164
    - laryngo-UES contractile reflex, 14
    - PES, 12
    - pharyngeal phase, 74
    - pharyngo-UES contractile reflex, 12
    - pressure, 136, 144, 178
    - relaxation, 5
  - Upper gastrointestinal (UGI) series, 45–47
  - Usual interstitial pneumonia (UIP)
    - clinical diagnosis, 181–182
    - histopathologic pattern, 178
    - HRCT, 182
- V**
- VCD. *See* Vocal cord dysfunction (VCD)
  - Vocal cord dysfunction (VCD)
    - autonomic balance and laryngeal hyperresponsiveness, 103–104
    - defined, 97–98
    - diagnosis, 99
    - dyspnea, 100
    - microaspiration and LPR, 103
    - organic and non-organic precipitants, 103
    - treatment, 111
- W**
- Wake time sleepiness, 135
- Z**
- Zenker’s diverticulum, 76
  - Zollinger–Ellison syndrome, 25